2022–2023 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates

CDC is collaborating with Vitalant Research Institute, American Red Cross, and Westat Inc. to conduct a nationwide COVID-19 seroprevalence survey of blood donors. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies.
Infection-induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection and refers to the percent of the population with anti-nucleocapsid antibodies.
Combined infection-Induced and Vaccination-Induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both, and refers to the percent of the population that has anti-spike antibodies, anti-nucleocapsid antibodies, or both.

This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022

美国疾病控制与预防中心与Vitalant研究学院、美国红十字会以及Westat公司携手开展全国范围内的COVID-19血清流行病学调查，针对献血者进行。去标识化的血液样本被检测以确定对SARS-CoV-2（导致COVID-19的病毒）的抗体，旨在深入了解美国人群中产生针对SARS-CoV-2抗体的比例，并追踪该比例随时间的变化。在美国，SARS-CoV-2感染及目前使用的COVID-19疫苗均能诱导产生抗刺突（抗-S）抗体，但只有感染才会产生抗核衣壳（抗-N）抗体。
感染引起的血清流行病学估计值反映了具有先前SARS-CoV-2感染抗体证据的群体比例，并指代具有抗核衣壳抗体的群体百分比。
感染诱导与疫苗接种诱导的血清流行病学估计值反映了具有先前SARS-CoV-2感染、COVID-19疫苗接种或两者兼备的抗体证据的群体比例，并指代具有抗刺突抗体、抗核衣壳抗体或两者兼备的群体百分比。
此链接链接至一个网页，展示全国献血者血清流行病学调查的数据。该网页提供可在https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022找到的交互式可视化数据。